Chennai-based medical technology firm Trivitron Healthcare is planning to invest around Rs 100 crore in next 12 to 18 months to complete its medical technology park, near Chennai. The company on Monday announced its plans to manufacture entire range of Critical Life Support Solutions (CLSS) on its own, as part of expanding its presence in the segment.
The company, which has already invested Rs 100 crore in the medical technology park developed in around 25 acre at Sriperumbudur, near Chennai. It has so far developed two manufacturing facilities in the park, one for ultrasound equipments and another one for diagnostics equipments manufacturing. The diagnostics equipment manufacturing facility would start commercial operations in next quarter, said GSK Velu, founder and managing director of Trivitron Healthcare.
“We are planning to develop two more facilities in the park, for some of the specialty diagnostic equipments and the CLSS, which includes intensive care, operating room and cardiac care products and solutions.” said Velu. The technology park would be completely operational in next two years, he added.
The company is also planning to raise around $100 million in the next two to three months to fund its acquisition plans on cardiology, imaging and diagnostic segments and to invest in the CLSS segment expansion, he said.
“In CLSS, we were present as a trader, and was catering to the top 100 healthcare facilities. Now, we are planning to manufacture the full range of these equipments on our own,” he said. The company is expecting almost 80 per cent of its CLSS business to come from the value range, which would be in the tier II, III cities which were not addressed by the company earlier. However, it would also cater the requirements of the premium market of multi national companies, he added.
The CLSS solutions segment consists of solutions and products for intensive care, operating room, dialysis care and cardiac care solutions like ventilator, patient monitor, defibrillator, ECG machine, stress test system, holter system, operating room design and execution, pendants and dialysis machine among various others.
The segment contributes to around Rs 3,000 crore of the Rs 17,000 crore medical equipment market, and is expected to grow at 15-20 per cent per annum during next 5 years. The company expects around Rs 100 crore revenue from the business, this year, said Velu.
“CLSS segment is a long term prospect for us, as operating room and intensive care are the most essential and basic needs for any corporate hospital,” he added.
Trivitron Group, which presently offers solutions in medical technology along with other business and joint ventures, has revenue of over Rs 400 crore in FY 2011.
